Schizophrenia Bulletin Advance Access originally published online on April 4, 2007
Schizophrenia Bulletin 2007 33(3):633-634; doi:10.1093/schbul/sbm027
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.
Editorial: Evidence-Based Therapeutics—Introducing the Cochrane Corner
| The first 10% of the full text of this article appears below. |
Therapeutic advances in schizophrenia are challenging, and novel drug development strategies that target diverse mechanisms are wanting. The drug discovery process has diverged little from the initial strategy of targeting D2 dopamine receptors following the discovery of the antipsychotic effect of chlorpromazine. The superior efficacy of clozapine in treatment-resistant patients was touted as a big advance in schizophrenia therapeutics promising superior effectiveness of the second-generation drugs in treating psychosis as well as other symptom domains and cognition impairments of schizophrenia. As suggested by the commercial success of these drugs, clinicians and consumers enthusiastically bought
1 To whom correspondence should be addressed; e-mail: wcarpent@mprc.umaryland.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Rosenheck, D. L. Leslie, and J. A. Doshi Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making Psychiatr Serv, May 1, 2008; 59(5): 515 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Adams, E. S. F. Coutinho, J. Davis, L. Duggan, S. Leucht, C. Li, and P. Tharyan Cochrane Schizophrenia Group Schizophr Bull, March 1, 2008; 34(2): 259 - 265. [Full Text] [PDF]
|
|